Hyderabad: Continuing its efforts to support the pharma and life sciences segments, Government of Telangana State together with pharma industry players announced a new Centre of Excellence (CoE) on Flow Chemistry in Hyderabad.
This initiative is aimed towards ensuring greater incorporation of flow chemistry techniques during pharma research and development and greater adoption of continuous synthesis for manufacturing of active pharma ingredients (APIs), the biologically active components of a drug product.
“This hub would be an enabler for the pharma industry in India to incorporate modern approaches from research and development to manufacturing and migration to greener and sustainable processes,” said Industries and IT Minister KT Rama Rao, in whose presence the consortium agreement for setting up the CoE was signed Thursday. Industries Principal Secretary Jayesh Ranjan was also present.
GV Prasad (Dr Reddy’s Laboratories Co-Chairman and Managing Director), Dr Satyanarayana Chava (Laurus Labs CEO), Shakthi Nagappan (Telangana Life Sciences and Pharma Director and Hyderabad Pharma City Chief Executive Officer) and Dr Srinivas Oruganti (Dr Reddy’s Institute of Life Sciences Director) signed the consortium agreement.
This hub is being set up at Dr Reddy’s Institute of Life Sciences (DRILS), a research institute of global eminence, and will receive funding and patronage from Dr Reddy’s Laboratories and Laurus Labs. The Government of Telangana will facilitate strategic support and scale up for the hub and encourage more industries to join the consortium and benefit from it.
“We remain committed to the growth of life sciences sector and consolidating our leadership position. Government of Telangana jointly with DRILS has envisaged establishment of this hub to support pharma companies in the city build scientific capabilities, support process development and also training,” said Jayesh Ranjan.
The new CoE is part of the larger effort of the State to become a $100 billion life sciences ecosystem by 2030, said Nagappan.
“We are happy to participate in this collaborative effort spearheaded by the Government of Telangana to bring the latest technologies in flow chemistry to the API and intermediate industry and to the State,” said DRL’ s GV Prasad.
“The CoE is aimed at developing and commercialising cleaner, greener, and safe chemical technologies for the chemical and pharmaceutical industry. The CoE will further cement Hyderabad’s position as a global leader in pharmaceuticals,” said Satyanarayana Chava.
With over 800 pharmaceutical companies, Hyderabad hosts the highest number of USFDA approved facilities globally and contributes to about 35% of India’s overall pharmaceutical production. The Indian pharma sector is dominated by the generic industry with API and API intermediates being the key constituents.